Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis
Vesterhus, Mette; Holm, Anders; Hov, Johannes Espolin Roksund; Nygård, Ståle; Schrumpf, Erik; Melum, Espen; Thorbjørnsen, Liv Wenche; Paulsen, Vemund; Lundin, Knut Erik Aslaksen; Dale, Inge; Gilja, Odd Helge; Zweers, Serge J.; Vatn, Morten H.; Schaap, Frank G.; Jansen, Peter L. M.; Ueland, Thor; Røsjø, Helge; Moum, Bjørn; Ponsioen, Cyriel Y.; Boberg, Kirsten Muri; Färkkilä, Martti; Karlsen, Tom Hemming; Lund-Johansen, Fridtjof
Journal article, Peer reviewed
MetadataShow full item record
Original versionVesterhus, M., Holm, A., Hov, J. R., Nygård, S., Schrumpf, E., Melum, E., ... & Gilja, O. H. (2017). Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. Journal of hepatology, 66(6), 1214-1222. https://doi.org/10.1016/j.jhep.2017.01.019
Background & Aims Prognostic biomarkers are lacking in primary sclerosing cholangitis, hampering patient care and the development of therapy. We aimed to identify novel protein biomarkers of disease severity and prognosis in primary sclerosing cholangitis (PSC). Methods Using a bead-based array targeting 63 proteins, we profiled a derivation panel of Norwegian endoscopic retrograde cholangiography bile samples (55 PSC, 20 disease controls) and a Finnish validation panel (34 PSC, 10 disease controls). Selected identified proteins were measured in serum from two Norwegian PSC cohorts (n = 167 [1992–2006] and n = 138 [2008–2012]), inflammatory bowel disease (n = 96) and healthy controls (n = 100). Results In the bile derivation panel, the levels of 14 proteins were different between PSC patients and controls (p <0.05); all were confirmed in the validation panel. Twenty-four proteins in the bile derivation panel were significantly (p <0.05) different between PSC patients with mild compared to severe cholangiographic changes (modified Amsterdam criteria); this was replicated for 18 proteins in the validation panel. Interleukin (IL)-8, matrix metallopeptidase (MMP)9/lipocalin (LCN)2-complex, S100A8/9, S100A12 and tryptophan hydroxylase (TPH)2 in the bile were associated with both a PSC diagnosis and grade of cholangiographic changes. Stratifying PSC patients according to tertiles of serum IL-8, but not MMP9/LCN2 and S100A12, provided excellent discrimination for transplant-free survival both in the serum derivation and validation cohort. Furthermore, IL-8 was associated with transplant-free survival in multivariable analyses in both serum panels independently of age and disease duration, indicating an independent influence on PSC progression. However, the Enhanced Liver Fibrosis (ELF®) test and Mayo risk score proved to be stronger predictors of transplant-free survival. Conclusions Based on assaying of biliary proteins, we have identified novel biliary and serum biomarkers as indicators of severity and prognosis in PSC. Lay summary Prognostic biomarkers are lacking in primary sclerosing cholangitis, hampering patient care and the development of therapy. We have identified inflammatory proteins including calprotectin and IL-8 as important indicators of disease severity and prognosis in bile and serum from patients with primary sclerosing cholangitis.